Merck’s KEYNOTE-C93 Phase 3 Trial Shows Significant PFS Improvement
Merck reported significant progression-free survival improvement with monotherapy in its KEYNOTE-C93 Phase 3 PD-1 inhibitor trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.